November 17, 2015
Gilead to early unblind Phase 3 study of Zydelig for chronic lymphocytic leukemia
Gilead Sciences, Inc. said Monday that its Phase 3 Study 115 evaluating Zydelig (idelalisib) added to standard therapy in previously-treated chronic lymphocytic leukemia (CLL) patients will be unblinded early.